Theriva approves stock plan increase through 2026 amendment
The Board of Theriva Biologics authorized a proposal to amend its 2020 Stock Incentive Plan by increasing the available shares by 2 million to 6.5 million. If approved, this will authorize additional grants of Awards under the Plan.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day